Letters to the Editor

Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up

Department of Haematology, Aarhus University Hospital, Aarhus, Denmark; Department of Haematology, Region Hospital Goedstrup, Herning
Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Mathematical Sciences, Aalborg University, Aalborg
Department of Oncology, Kuopio University Hospital Cancer Center, Kuopio, Finland; Faculty of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio
Department of Oncology, St Olav University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of science and technology (NTNU), Trondheim, Norway
Department of Radiation Sciences, Umeå University, Umeå, Sweden
Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
Research Programs Unit/Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki
Department of Oncology, Oslo University Hospital, Oslo, Norway
Department of Oncology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo, Norway
Department of Oncology, Skane University Hospital, Lund, Sweden; Medical Oncology, Lund University, Lund, Sweden
Department of Hematology, Aalborg University Hospital, Aalborg
Cancer Centre, Oulu University Hospital, Oulu
Department of Radiation Sciences, Umeå University, Umeå, Sweden
Department of Clinical Science and Education, Södersjukhuste, Karolinska Insitutet, Stockholm, Sweden; Haematology Centre, Karolinska University Hospital, Stockholm, Sweden
Department of Haematology, Aarhus University Hospital, Aarhus
Research Programs Unit/Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere
Haematologica Early view Mar 28, 2024 https://doi.org/10.3324/haematol.2024.285207